Houston Chronicle (10.28.06) - Friday, November 03, 2006
Leigh Hopper

That component is epigallocatechin gallate (EGCG). The flavonoid has anti-inflammatory and anti-microbial properties, and cancer drugs based on it are now in clinical trials.

Researchers have known for some time that EGCG inhibits HIV in lab experiments; the new research suggests how. Scientists from Baylor College of Medicine and the University of Sheffield have found that the EGCG molecule binds to the T- cell receptor site at which HIV seeks to attach to the cell.

Dr. Christina Nance of Baylor and Texas Children's Hospital said she and colleagues used nuclear magnetic resonance spectroscopy to examine the structures by which EGCG, the HIV surface protein gp120 and CD4 molecules bind together. They noted the frequencies emitted by the hydrogen, carbon, and nitrogen atoms that make up the molecules and fed the data into a computer, which produced a molecular model showing that EGCG and HIV shared the same "binding pocket" on the CD4 cells. "One of the promising factors is that because this is a small molecule and binds to the same exact binding pocket as gp120, it may not inhibit the [normal] function of the CD4 molecule," Nance said.

In the laboratory, Nance said the amount of EGCG needed to inhibit HIV was about the same as that in two cups of green tea. She stressed, however, that any EGCG-based drug "would be part of a cocktail of drugs," and she said she does not recommend that people drink large amounts of green tea in the hope of preventing HIV infection.

The full report, "Epigallocatechin Gallate, the Main Polyphenol in Green Tea, Binds to the T-Cell Receptor, CD4: Potential for HIV-1 Therapy," was published online in the Journal of Allergy and Clinical Immunology" (doi: 10.1016/j.jaci.2006.08.016).
061103
AD062105

Copyright © 2006 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .